<DOC>
	<DOCNO>NCT02184897</DOCNO>
	<brief_summary>Twenty four patient multiple myeloma randomize either AM group ( administration lenograstim 8 ) PM group ( administration lenograstim 6 ) . Apheresis hematopoietic stem cell start 10 D5 AM group 8 D4 PM group , respectively . Pharmacokinetic data lenograstim correlate pharmacodynamic data CD34+ cell count , absolute neutrophil cell count hematopoeitic progenitor cell count . In addition , yield stem cell collection two arm analyze .</brief_summary>
	<brief_title>Pharmacokinetic Pharmacodynamic Study Lenograstim Hematopoietic Stem Cell Mobilization</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>age : 17 year , 65 year old informed consent ECOG 01 autologous stem cell transplant candidate among patient multiple myeloma prior history hematopoetic stem cell transplantation history failure mobilize hematopoietic stem cell history GCSF administration within 2 week enrollment study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>